Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction-associated steatotic liver disease, and other cardio-kidney-metabolic conditions.

Given the exceptionally high rates of obesity and type 2 diabetes in the Gulf region, triple-hormone receptor agonists represent the next frontier in metabolic nephroprotection.